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Multiple myeloma(MM)is a malignantplasmacell disorder andmorethan30%ofpatients withthis pathologydevelop osteolytic
lesionsin the jaw.Either pamidronateorzoledronic acid isrecommended in patients with MM whohaveoneormorelytic lesions.
However, bisphosphonate-related osteonecrosis of the jaws (BRONJ) has been described as a complication associated with their
use. Otherwise, the use of endosseous implants in oral rehabilitation is a well-established procedure, with good long-term success
although systemic factors may aﬀect the bone healing around dental implants. We report the ﬁrst case reported of MM adjacent
to a mandibular dental implant in a patient who developed BRONJ in the same area after intravenous zoledronate treatment. We
discuss possible pathogeny of this particular and interesting phenomena.
1.Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder
that accounts for approximately 10% of all hematologic
cancers [1]. It develops mainly in men aged from 50 to
80 years, with a mean of 66 years [2]. More than 30%
of patients with MM develop osteolytic lesions in the jaw
[3]. Those lesions are more frequent in the posterior region
of the mandible [4]. The oral manifestations of MM are
ﬁrst signs of the disease in about 14% of the patients and
may include swelling, pain, bleeding, mobile teeth, amyloid
deposits, root resorption and mobility, labial anesthesia,
and jaw radiolucencies and fractures [2, 3]. Histological
analysis of bone lesions usually reveals plasmacytoid cells,
with round, eccentric nuclei with ﬁne granular chromatin
and evident nucleolus, characteristics of a solid malignant
hematopoietic neoplasm [1].
Restorativetreatmentofmissing teethviadentaltitanium
implants has a considerable eﬀect on oral health, and quality
of life is improved as compared to conventional removable
denture prostheses [5]. Various factors have been implicated
in the success of implants, but these studies have been large-
ly limited to patients with “normal” hard and soft tissues.
Moreover, systemic factors may aﬀect the bone healing
around dental implants [6, 7].
Either pamidronate (90mg intravenously over at least 2
hours every 4 weeks) or zoledronic acid (4mg intravenously
over 15–30 minutes every 4 weeks) are recommended in
patients with MM who have one or more lytic lesions on
skeletal roentgenograms. The administration ofbisphospho-
nates signiﬁcantly reduces the number of skeletal events
(pathologicfracture, needforirradiationorsurgery onbone,
and spinal cord compression). The typical recommendation
initially was to continue bisphosphonates indeﬁnitely at
monthly intervals [8]. However, by 2003, osteonecrosis of
the jaws or bisphosphonate-related osteonecrosis of the
jaws (BRONJ) has been described as a new complication
associated with their use [9]. Several studies have focused on
the risk factors for developing BRONJ. Treatment with high
potency (nitrogenated) intravenous bisphosphonates such
as zoledronic acid and pamidronate, and dental extractions
are important risk factors. The duration of bisphosphonate
treatment, the number of infusions, and the total infusion
hours may also be risk factors for BRONJ [10, 11].
We report a case of MM adjacent to a mandibular dental
implant in a patient who developed BRONJ in the same area2 Case Reports in Dentistry
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Figure 1: (a) Panoramic radiograph revealing periapical radiolu-
cency in endodonticallytreated leftmandibularpremolar,when pa-
tient was completely healthy (March 2006). (b) Panoramic radio-
graph showing dental implants before ﬁnal restoration. Implants
were completely osseointegrated, and no mandibular lesions were
observed (September 2006).
after intravenous zoledronate treatment. To our knowledge,
this is the ﬁrst case reported with this particular and interest-
ing evolution.
2.CaseReport
A 59-year-old Caucasian male patient was referred to our
department in March 2007 for mandibular evaluation. In
April 2006, when the patient was completely healthy, he
underwent extraction of ﬁrst left mandibular premolar
with failed endodontic treatment (Figure 1(a)) and two in-
traosseous implants placement in the left mandibular molar
region one month after. Dental implants were placed using a
two-step process, and, six months after (October2006), were
uncovered and restored, uneventfully (Figure 1(b)).
The patient received the diagnosis of MM in February
2007 (IgA lambda, Durie and Salmon’s stage III A, ISS 3).
WhenMMwasdiagnosed,thepatientshowed widelyskeletal
aﬀection, including cranial calotte, thoracic and lumbar
vertebral spine. Calcium, creatinine, and hemoglobin were
in normal levels. The hematologist referred the patient to
our department in March 2007 because of mandibular pain
and swelling. Clinical examination revealed left mandibu-
lar cortical expansion without bone exposure or ﬁstula in
the aﬀected area. No labial paresthesias were referred. A
panoramic radiograph showed a large radiolucency adjacent
to the left implant and second left mandibular molar
(Figure 1(a)).AdiagnosisofmandibularinvolvementofMM
was proposed. As induction therapy, the treatment included
six alternating cycles of vincristine, carmustine, melphalan,
cyclophosphamide, prednisone (VBMCP) and vincristine,
carmustine, doxorubicin and dexamethasone (VBAD) (each
ﬁve/four weeks, resp.), ending in July 2007. The patient
developed a very good partial response, without plasmatic
cells in bone marrow and monoclonal pick in electrophore-
sis, but with positive immunoﬁxation in serum. Consoli-
dation therapy consisted in melphalan, alpha interpheron
2b, and autologous stem cell transplantation, carried out in
October 2007. The patient also received 17 doses of Zole-
dronic Acid (4mg/dose, once per month). A new panoramic
radiograph performed seven months after starting therapy
revealed a complete regression of the mandibular lesion
(Figure 2), supporting previous diagnosis of mandibular
involvement of MM.
The patient presented again in September 2008 com-
plaining of discomfort in the left mandibular molar area.
Left inferior labial paresthesia was referred. Intraoral exam-
ination revealed that the alveolar bone adjacent to the left
implant was exposed with a purulent discharge (Figure 3).
The panoramic radiography provided poor diagnostic
information, showing only low-diﬀusion radiolucency in
the aﬀected area (Figure 4(a)). Computerized tomogra-
phy revealed low- and high-density areas in the alveolar
process involving left mandibular implant and giving an
aspect of necrotic bone (Figure 4(b)). Treatment consisted
of simultaneous amoxicillin (4gr/day) and clavulanate
(250mg/day) with chlorhexidine mouthwash. A biopsy of
thelesionperformed shortly thereaftershowed bonenecrosis
with superﬁcial contamination with oral organisms. Elec-
trophoresis was absolutely normal. No evidence of MM
was detected. A diagnosis of BRONJ was made. After 3
months, the pain did not disappear and bone exposure had
not reduced (Figure 5(a)). Then, the mobile fragment of
exposed necrotic bone including left implant was removed
under local anesthesia (Figure 5(b)). The specimen was
submitted for microscopic evaluation, and diagnosis was
bone sequestrum with microbial colonies of Actinomyces.
After 1 month, the pain had almost completely dis-
appeared. The lesion was asymptomatic and soft tissues
healed completely. At present, the patient is still under
antineoplastic therapy (bortezomib and dexamethasone) for
refractary vertebral MM, but zoledronate therapy has been
discontinued.
3.Discussion
Current dental and orthopedic titanium implants have been
developedbased on theconcept“bone-titaniumintegration”
and are so-called “osseointegrated implants”. In addition
to the bone interface, however, a considerable area of the
implant surface may initially be in intimate contact with
bonemarrow. PossibleinteractionsbetweenimplantsurfacesCase Reports in Dentistry 3
(a)
(b)
Figure 2: (a) Panoramic radiograph showed a large lytic lesion
adjacent to the left implant and second left mandibular molar,
diagnosed as MM (March 2007). (b) A new panoramic radiograph
performed seven months after starting therapy revealed a complete
regression of the mandibular lesion, supporting previous diagnosis
of mandibular involvement of MM.
Figure 3: An extensive area of necrotic bone (arrow) is exposed
adjacent to the left implant with purulent discharge (September
2008).
and bone marrow cells could be a critical question in
patients aﬀected by hematologic malignancies. Rahal et al.
[12] presented an experimental model placing titanium
implants in the femur and bone marrow of mice. After 5
months after implantation, the titanium surface remained
in direct contact with bone marrow cells. Prominent giant
multinucleated cells with phagocytic inclusion, not seen in




radiolucency around the left implant. (b) Computerized tomog-
raphy image revealing necrotic bone involving left mandibular
implant (September 2008).
to foreign bodies within the bone marrow itself could aﬀect
the immune capacity of the host or predispose to potentially
neoplastic dysregulation of bone marrow cells.
Otherwise, a more recent experimental work in mice
[13] provides no evidence to suggest that titanium implants
in contact with mouse bone marrow carry a long-term
risk of focal hemopoietic perturbations or marrow-derived
B lineage neoplasm. The authors described a harmonious
“myelointegration”. However, they found that an implant-
marrow interface with associated giant cells persists for at
least 1.5 years. Precursor B cells show early increases in
number and proliferative activity. At later intervals, however,
they do not diﬀer signiﬁcantly from controls, and there are
no perturbations in spatial localization of either B lineage
cells or DNA-synthesizing hemopoietic cells. Thus, myeloin-
tegration of dental implants in a previous healthy patient
who develops a MM during osseointegration is a diﬃcult
and interesting question. There is a single case reported in
t h el i t e r a t u r eo fap a t i e n ta ﬀected by a plasmacytoma of the
spine and developed a new plasmacytoma of the mandible 3
years subsequent to the insertion of a dental implant. This
second solitary lesion occurred 15 years after the ﬁrst one,
and without signs of conversion to MM [14].
As the jaws have a faster bone turnover rate (10 times
higher than other bones), this requires adaptability and
upregulation of the osteoblast and osteoclast function [15].
Otherwise, previous cases of plasma cell disorders preceded
by skeletal trauma have been described [16–18]. Hussein et
al. [18] hypothesized that trauma totheskeletalsystem could
cause the release of cytokines leading to the proliferation of4 Case Reports in Dentistry
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Figure 5: (a) Exposed necrotic bone around the left implant after
three months of antibiotherapy. (b) Image of the resected specimen
of bone sequestrum including left implant.
plasma and stromal cells in the bone. Thus, dental implants
could have been represented a mandibular trauma and pro-
ducedcontinued inﬂammation leading tooverstimulation of
plasma cells in the case reported.
A single case of BRONJ around dental implants related
to bone metastases of breast cancer has been reported [19],
but the development of BRONJ adjacent to a dental implant
in the same area previously aﬀected by MM represents an
extremely rare condition not previously published. Unfortu-
nately, a single case report has made it diﬃcult to determine
cause and be conﬁdent of its behavior.
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